Assessment of immune function after short-term administration of recombinant human growth hormone in healthy young males.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The aim of this study is to evaluate the immunomodulatory effects of short-term administration of recombinant GH (rhGH) in healthy young males.

Why It Was Studied

IGF-I plasma concentration and flow cytometry data were generated at baseline and days 8, 15, 22 and 29 post injection.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, men only.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Health, Human Growth Hormone, Immune System, Insulin-Like Growth Factor I, Killer Cells, Natural, Lymphocyte Count and Recombinant Proteins.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 2011 (European journal of applied physiology), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.